Is cabozantinib a targeted drug? Belong to several generations

Cabozantinib (Cabozantinib) is a targeted drug. It is a multi-target tyrosine kinase inhibitor that acts on multiple receptor kinases and receptor tyrosine kinases. In vitro biochemical and/or cellular assays show that cabozantinib inhibits the tyrosine kinase activity of MET, VEGFR-1, -2 and -3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT-3 and TIE-2. These receptor tyrosine kinases are involved in normal cellular functions and pathological processes, such as tumorigenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.

In advanced renal cell carcinoma, differentiated thyroid cancer, and hepatocellular carcinoma, cabozantinib has been shown to prolong the survival of previously treated patients without their disease worsening. These patients have poor prognosis and unmet medical needs. The results also showed that cabozantinib helped patients live longer. Cabozantinib also provided clinically relevant benefits in patients with previously untreated intermediate or high-risk disease, delaying cancer progression and the need for additional treatments. The side effects of cabozantinib are similar to those of other tyrosine kinase inhibitors, and they are considered manageable.

The original drug Cabozantinib is not marketed in the country and therefore cannot be included in medical insurance. The original cabozantinib drug marketed overseas includes Japanese, Turkish and European versions. The price of tablets may be more than 30,000 yuan, and the price of capsule preparations may be more than 40,000 yuan (prices may fluctuate due to exchange rates). There are also generic drugs produced in other countries overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs. For example, the price of pharmaceuticals produced by Bangladeshi pharmaceutical factories may be more than 2,000 yuan (the price may fluctuate due to the exchange rate), which is relatively cheap.